Pharma Focus America

ScaleReady introduces $20 million G-Rex® Grant Program to propel advancements in Cell and Gene Therapy (CGT) Development and Manufacturing

Thursday, May 30, 2024

ScaleReady, along with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReady, have introduced the G-Rex® Grant Program, an initiative valued at $20 million designed to propel the advancement of cell and gene therapies (CGT).

This program will offer academic and commercial institutions engaged in pre-clinical research, process development, and GMP manufacturing of CGT with resources and services to implement or enhance a highly efficient G-Rex® based cell manufacturing platform. Qualified programs can receive up to $300,000 in G-Rex® devices, critical reagents, capital equipment, application support, and manufacturing consultation services.

Wilson Wolf Manufacturing, expressed eagerness for the program, noting G-Rex®'s extensive usage in CGT trials and approved therapies. He highlighted their capacity to streamline manufacturing processes, significantly saving time and costs while enhancing yield and potency.

ScaleReady, lauded the program as transformative, stressing G-Rex®'s unique ability to integrate research, development, and manufacturing functions. By equipping researchers with top-notch tools and expertise, the initiative aims to expedite development and enhance the manufacturability of potential life-saving treatments.

Bio-Techne's Protein Sciences Segment, reaffirmed their commitment to supporting groundbreaking therapies, indicating that the G-Rex® Grant Program aligns seamlessly with this mission.

The program will prioritize applicants demonstrating a clear rationale for needing a G-Rex® Grant, willingness to collaborate, successful program management experience, and well-defined deliverables. The application process is streamlined to foster collaborative discussions to refine program goals.

Participating recipients can anticipate accelerated development timelines, smoother transitions to GMP manufacturing, and stronger data packages for IND applications. Ultimately, the program seeks to expedite clinical data generation, simplify the development process, enhance manufacturability, throughput, and scalability of CGT programs, thereby increasing patient access to potentially life-saving therapies.

 

Source: prnewswire.com

Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024